Syros Pharmaceuticals, Inc. (LON:0LC7)

Syros Pharmaceuticals Statistics

Total Valuation

LON:0LC7 has a market cap or net worth of GBP 3,939. The enterprise value is 1.44 million.

Market Cap	3,939
Enterprise Value	1.44M

Important Dates

The next estimated earnings date is Monday, March 2, 2026.

Earnings Date	Mar 2, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	26.83M
Shares Outstanding	n/a
Shares Change (YoY)	n/a
Shares Change (QoQ)	+0.17%
Owned by Insiders (%)	0.46%
Owned by Institutions (%)	1.99%
Float	26.71M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.01
PB Ratio	-0.00
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-0.02
EV / Sales	5.07
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-0.02

Financial Position

The company has a current ratio of 2.25

Current Ratio	2.25
Quick Ratio	2.05
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	-0.60
Interest Coverage	-20.92

Financial Efficiency

Return on equity (ROE) is -776.96% and return on invested capital (ROIC) is -94.28%.

Return on Equity (ROE)	-776.96%
Return on Assets (ROA)	-59.88%
Return on Invested Capital (ROIC)	-94.28%
Return on Capital Employed (ROCE)	-197.02%
Weighted Average Cost of Capital (WACC)	6.99%
Revenue Per Employee	4,235
Profits Per Employee	-1.07M
Employee Count	68
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -99.54% in the last 52 weeks. The beta is 1.08, so LON:0LC7's price volatility has been similar to the market average.

Beta (5Y)	1.08
52-Week Price Change	-99.54%
50-Day Moving Average	0.00
200-Day Moving Average	0.01
Relative Strength Index (RSI)	44.63
Average Volume (20 Days)	1,744

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	1.67

Income Statement

In the last 12 months, LON:0LC7 had revenue of GBP 287,995 and -72.98 million in losses. Loss per share was -1.98.

Revenue	287,995
Gross Profit	-65.84M
Operating Income	-83.21M
Pretax Income	-72.98M
Net Income	-72.98M
EBITDA	-82.21M
EBIT	-83.21M
Loss Per Share	-1.98

Balance Sheet

The company has 43.48 million in cash and 44.93 million in debt, with a net cash position of -1.46 million.

Cash & Cash Equivalents	43.48M
Total Debt	44.93M
Net Cash	-1.46M
Net Cash Per Share	n/a
Equity (Book Value)	-8.30M
Book Value Per Share	-0.31
Working Capital	26.52M

Cash Flow

In the last 12 months, operating cash flow was -74.62 million and capital expenditures -28,352, giving a free cash flow of -74.65 million.

Operating Cash Flow	-74.62M
Capital Expenditures	-28,352
Free Cash Flow	-74.65M
FCF Per Share	n/a

Margins

Gross Margin	n/a
Operating Margin	-28,891.67%
Pretax Margin	-25,340.64%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

LON:0LC7 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-31.77%
Shareholder Yield	-31.77%
Earnings Yield	-1,852,663.77%
FCF Yield	-1,895,071.53%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on September 19, 2022. It was a reverse split with a ratio of 0.1.

Last Split Date	Sep 19, 2022
Split Type	Reverse
Split Ratio	0.1

Scores

LON:0LC7 has an Altman Z-Score of -15.52. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-15.52
Piotroski F-Score	n/a